MUC1 100mer peptide + poly-ICLC

This investigational cancer vaccine consists of a synthetic 100-amino acid peptide (100mer) derived from the Mucin 1 (MUC1) glycoprotein, combined with the adjuvant Poly-ICLC (Hiltonol). Developed by Dr. Olivera Finn at the University of Pittsburgh, the vaccine targets the aberrantly glycosylated MUC1 protein, which is overexpressed in over 80% of human cancers, including non-small cell lung cancer (NSCLC) and neuroendocrine tumors. The MUC1 100mer peptide contains five tandem repeats of a 20-amino acid sequence from the MUC1 extracellular domain. Poly-ICLC, a synthetic double-stranded RNA and Toll-like receptor 3 (TLR3) agonist, acts as a potent adjuvant to enhance the Th1-mediated immune response against the MUC1 antigen. The vaccine is administered subcutaneously to elicit tumor-specific T-cell immunity in patients with localized or advanced disease following standard-of-care treatments.

Brand names

Hiltonol

Other names

MUC1 Peptide - Poly-ICLC VaccineMUC-1 Peptide - Poly-ICLC VaccineMUC 1 Peptide - Poly-ICLC VaccineMUC1 100mer peptide vaccineMUC-1 100mer peptide vaccineMUC 1 100mer peptide vaccineMUC1-poly-ICLCMUC-1-poly-ICLCMUC 1-poly-ICLCMUC1-poly-ICLC-Olivera Finn vaccineMUC-1-poly-ICLC-Olivera Finn vaccineMUC 1-poly-ICLC-Olivera Finn vaccine